AMSTERDAM, The Netherlands and Washington, D.C – At the 2017 American College of Cardiology’s Annual Scientific Session & Expo (ACC.17), Royal Philips (NYSE: PHG, AEX: PHIA) will showcase a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions. As a global leader in health technology, Philips will demonstrate how its suite of cardiology solutions comprising imaging systems, smart devices, clinical informatics and services, help transform care pathways and provide clinical insights that contribute to life-changing opportunities. With a continued shift away from fee-for-service payment models and transition from volume to value-based care, healthcare organizations are challenged to help prevent and reduce costs while improving the quality of care. At ACC.17, Philips will demonstrate how its comprehensive suite of cardiology solutions enable hospitals to reduce system response and streamline processes to improve the management of cardiac patients in emergency situations. By enabling seamless communication across the health continuum, from home to hospital and back, Philips is bridging the gap in patient flow before entrance to the hospital and after discharge, which is critical to reducing costs and achieving optimal outcomes for patients. “As a focused leader in health technology, Philips aims to provide integrated solutions across the health continuum from healthy living and prevention, to diagnosis, treatment and after care at home, in order to combat the rising incidence of chronic diseases such as those caused by cardiovascular conditions,” said Bert van Meurs, Business Leader, Image Guided Therapy. “We offer a broad portfolio of innovative solutions to optimize the image-guided minimally invasive treatment of cardiovascular conditions, while managing costs.” Philips will exhibit the company’s advanced, connected health offerings in the cardiology space at ACC.17, including: Also at this year’s conference, new groundbreaking iFR (instant wave-Free Ratio) outcome results from over 4,500 patients will be announced on Saturday, March 18 at 10:45 a.m. The data, which represent the largest randomized coronary physiology outcome studies to date, has the potential to help shape revascularization guidelines. The announcement and presentation of the outcome data follows Philips’ announcement last year of three clinical studies designed to assess the safety of deferring cardiovascular interventions using the company’s proprietary iFR pressure measurement technology.
In addition to presenting data around the benefits of iFR technology, Philips will host “Cardiology Talks,” a program of short talks and conversation on key findings, trends and ideas impacting the cardiology specialty today. During the 20-minute sessions held in the Forum area of the Philips booth, clinicians, scientists and thought leaders will share their experiences and perspectives, discuss innovations, and invite attendees to join in the conversation. To view the full schedule of sessions, visit the Philips Cardiology Talks page.
For more information on Philips' integrated cardiology solutions, visit Philip’s booth (#1024) at ACC.17 or visit the Philips event page. Follow the #ACC17 conversation via @PhilipsLiveFrom and @PhilipsHealth.
Azurion is Philips’ next generation image-guided therapy platform and the new core of its integrated solutions portfolio. Azurion supports a full range of configurations across a broad spectrum of image-guided therapy procedures. These include configurations for high volume routine procedures and flexible configurations for advanced procedures. Harnessing vital procedural information from various sources, such as imaging systems, interventional devices, navigation tools and patient health records, Azurion provides interventional staff members with the control and information they need to perform procedures efficiently.
Alicia Cafardi Philips Group Press Office Tel: +1 412-523-9616 Email: Alicia.Cafardi@philips.com
Twitter: @aliciacafardi
About Royal Philips: Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.